quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·10d
PRRelease
Allogene Therapeutics Inc. logo
Natera Inc. logo

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

ALLO· Allogene Therapeutics Inc.NTRA· Natera Inc.
Health Care
Original source

Companies

  • ALLO
    Allogene Therapeutics Inc.
    Health Care
  • NTRA
    Natera Inc.
    Health Care

Recent analyst ratings

  • Apr 16ALLOUpdateAnalyst-
  • Apr 14NTRAUpdateWilliam Blair-
  • Apr 10ALLOUpdateJefferies$6.00
  • Jan 9ALLOUpdateCitizens JMP$5.00
  • Jan 7NTRAUpdateCitigroup$300.00
  • Dec 2NTRAUpdateMorgan Stanley$265.00

Related

  • SEC6h
    SEC Form DEFA14A filed by Natera Inc.
  • SEC7h
    SEC Form DEF 14A filed by Natera Inc.
  • INSIDER7h
    SVP, Finance Yoshiyama Annie sold $22,144 worth of shares (9,586 units at $2.31), decreasing direct ownership by 7% to 124,517 units (SEC Form 4) to satisfy withholding tax
  • INSIDER2d
    SEC Form 4 filed by Sheena Jonathan
  • PR2d
    Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
  • SEC3d
    SEC Form PRE 14A filed by Allogene Therapeutics Inc.
  • PR3d
    Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
  • PR7d
    Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022